We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 Blue-Chip Marvels Trading At Unmissable Prices: GlaxoSmithKline plc, easyJet plc And National Grid plc

Royston Wild explains why GlaxoSmithKline plc (LON: GSK), easyJet plc (LON: EZJ) and National Grid plc (LON: NG) should be on the shopping list of all savvy value seekers.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Today I am looking at three stocks that provide stunning bang for one’s buck.

GlaxoSmithKline

The problem of serious patent losses continues to stunt investor appetite for pharma plays such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Shares in the firm have steadily declined in recent weeks and have shed more than 10% since mid-April, but I believe that this recent weakness represents a fresh buying opportunity.

Should you buy easyJet Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

You see, while revenues losses from the likes of its Advair asthma treatment are likely to remain a bugbear, GlaxoSmithKline is throwing everything including the kitchen sink at producing the next line of profits drivers. The company currently has around 40 products in Phase II or III development, and while the business of drugs development is often fraught with delays and heavy capital drain, I reckon GlaxoSmithKline’s exceptional track record in these matters should underpin excellent earnings growth — indeed, its Tivicay anti-HIV drug is touted as a future superstar.

Of course the pills play’s bubbly pipeline is not set to offset the impact of key exclusivity losses just yet, and GlaxoSmithKline is anticipated to punch a further 11% earnings decline in 2015. Still, the fruits of these labours are expected to translate into tangible gains from next year, and a 7% uptick is currently pencilled in by the City. Accordingly a P/E multiple of 16.8 times for this year falls to just 15.5 times for 2015, around the watermark of 15 times that indicates attractive value.

On top of this, GlaxoSmithKline is also on course to maintain market-beating dividend yields in the coming years, the company having pledged payouts of 80p per share through to 2017. These figures create a large yield of 5.5% during this period, and I believe a backcloth of strong earnings growth should drive rewards still higher looking further down the road.

easyJet

I reckon that budget carrier easyJet (LSE: EZJ) is a sound choice for those seeking delicious value for money. Demand for cheap travel from holidaymakers and business travellers alike is showing no signs of slowing, a trend which prompted Europe’s airlines to boost the number of seats in the short-haul market to 20.2 million seats in October-March, up 5.2% on an annualised basis.

With easyJet expanding the number of planes, routes and airports from which it operates — and boosted by the likelihood of lower fuel prices looking ahead — I believe earnings should continue soaring higher. This view is shared by the number crunchers, and the airline is expected to punch growth of 14% and 11% for the years concluding September 2015 and 2016 correspondingly. As a result the carrier boasts ultra-low P/E ratings of 13.2 times and 11.9 times for these years.

In line with this bubbly earnings outlook, easyJet is predicted to hike the dividend from 45.4p per share last year to 53.1p in the current period, producing a decent yield of 3.1%. And expectations of a further raise in 2016, to 59.5p, drives the yield to a juicy 3.5%.

National Grid

I believe that National Grid’s (LSE: NG) (NYSE: NGG.US) vertically-integrated operations make it a more attractive selection that any of the UK’s other utilities giants, its model allowing it to dodge regulatory scrutiny over its profitability and therefore any potentially-draconian action. Rather, the London firm is benefitting from OFGEM’s RIIO price controls — measures designed to curtail capital seepage — a terrific omen for earnings and dividend hunters.

With National Grid also aggressively building its asset base in the UK as well as North America, I believe shareholder returns should head for the skies in the coming years. In the meantime, the effect of heavy investment is expected to push earnings fractionally lower in the year concluding March 2016, although a 3% bounce in the following 12 months is a sign of things to come. And this predicted uptick also pushes a decent earnings multiple of 15.6 times for this year to an even-better 15.1 times next year.

Subsequently the City also expects dividends to continue steadily rising, and a payment of 42.87p per share last year is anticipated to advance to 44.4p in the current period, resulting in a monster 5% yield. And this rises to 5.1% for 2017 amid expectations of a 45.6p reward.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Tree lined "tunnel" in the English countryside of West Sussex in autumn
Investing Articles

3 UK shares to consider holding in a Stocks and Shares ISA for a decade

Mark Hartley explains why he thinks these three stocks would make great additions to a long-term Stocks and Shares ISA…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Where should value investors look for stocks in June?

Value investors looking for stocks to buy might be uneasy with artificial intelligence. But other industries look much more attractive…

Read more »

Investing Articles

The latest broker outlooks on Greggs shares look wacky, so what’s happening?

Analyst price targets for Greggs shares are creating some mixed sentiments on where the high-street baker might go next in…

Read more »

Caerphilly Castle, and reflection in the moat.
Investing Articles

2 FTSE 100 dividend stocks that stand out for shareholder returns

Andrew Mackie highlights two FTSE 100 dividend stocks where disciplined capital allocation could continue driving shareholder returns.

Read more »

Senior Adult Black Female Tourist Admiring London
Investing Articles

Just 9% of us can expect a ‘comfortable’ retirement! Could UK shares be the answer?

Millions of Brits could miss out on the retirement of their dreams. Might they avoid this by investing in UK…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

3 passive income shares to consider buying for a 7% yield

Harvey Jones picks out three UK income shares that offer terrific dividends and are trading at tempting valuations. None of…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

How much just £4,160 invested in Rolls-Royce shares 5 years ago is worth now

Rolls-Royce shares have been on a remarkable run of late. Ken Hall takes a look at the key drivers and…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

The FTSE 100’s Howden Joinery just made a bold move — should investors care?

Andrew Mackie looks at the FTSE 100’s Howden Joinery and its move into online kitchens, asking what the acquisition means…

Read more »